The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 13, U.S. pharmaceutical giant Bristol-Myers Squibb entered into a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals. The deal could be worth more than $15 billion in total value.